An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Trial Profile

An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms AZURE
  • Sponsors Bayer
  • Most Recent Events

    • 20 Mar 2017 Planned End Date changed from 1 Mar 2019 to 9 Dec 2019.
    • 20 Mar 2017 Planned primary completion date changed from 1 Mar 2019 to 9 Dec 2019.
    • 15 Nov 2016 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top